and spent a great deal of time on Internet chat sites, to the dismay of her family. This activity does not speak at all to the question of whether the BD diagnosis was accurate. In the second case, the patient was diagnosed with BD and did not feel that valproate helped her. Again, this fact by itself does not prove that the BD diagnosis was inaccurate. Indeed, response to a single mood stabilizer occurs, at best, in only one-third of patients with BD (1) . Many patients with BD who respond to lithium do not respond to valproate, and vice versa (2) . The correspondent's complaint in the second case appears chiefly to be about the treatments for BD and not about the diagnosis itself. It is our sense that many clinicians hesitate to diagnose BD because of their dissatisfaction with available treatments. This is a practical problem; hopefully, it will be less of an issue as newer, more tolerable mood stabilizers are developed. However, this practical problem has nothing to do with the empirical fact of whether someone meets or does not meet criteria for BD, based on an accurate and complete examination of symptoms and history. It is also interesting that both patients apparently responded poorly to standard unipolar treatments (antidepressants), yet the author does not conclude that this argues against the unipolar diagnosis. In fact, poor outcomes with antidepressants are quite common in the histories of patients with BD, as we reviewed in our paper.
We therefore just do not see how these 2 cases at all justify a claim for overdiagnosis of BD. We agree that there are cases in which BD is erroneously diagnosed. Possibly, the vague use of the term "mood swings" may lead to a mistaken diagnosis of BD in a person with a personality disorder or some other condition. However, in our paper, we described much more specific criteria than vague mood swings. Importantly, to our knowledge there is absolutely no published or presented empirical evidence supporting the idea that BD is overdiagnosed. There is, as we reviewed in our paper, plenty of evidence to the contrary-that BD has been and remains underdiagnosed. Even if occasional cases of erroneous diagnosis were found, it would be necessary to show that such cases are more frequent than the misdiagnosis of BD before one could claim that BD overall is overdiagnosed. It is a simple fact of scientific method, highlighted by the evidence-based medicine literature (3) , that case reports do not refute empirical studies. There is no appreciable evidence that BD is overdiagnosed.
S Nassir Ghaemi, MD James Y Ko, AB Frederick K Goodwin, MD Cambridge, Massachusetts
Quetiapine-Induced Leucopenia: Possible Dosage-Related Phenomenon
Dear Editor:
Quetiapine is as effective as haloperidol and chlorpromazine in relieving both the positive and negative symptoms of schizophrenia at dosages ranging from 150 to 750 mg daily (1-3).
In premarketing placebo-controlled trials, quetiapine use has been associated with a dosage-related decrease in total and free thyroxin (T4), with transient leukopenia, and with an elevation from baseline in cholesterol, triglyceride, and hepatic transaminases (4).
Case Report
MM is a 41-year-old woman diagnosed with schizophrenia at age 22 years. While taking chlorpromazine 600 mg daily, she was well (that is, her schizophrenia was episodic, with no interepisode residual symptoms) and functioned independently in the community for over 18 years.
Nonadherence to treatment preceded the recurrence of positive symptoms, social withdrawal, and poor personal hygiene, which led to her readmission to a psychiatric hospital for over 7 months in 2001. Pharmacotherapy with optimal dosages of olanzapine and risperidone did not appreciably improve her target symptoms. After haloperidol 10 mg daily was commenced, improvement in the target symptoms was evident, and she was discharged home. She was readmitted 7 weeks later because she had not adhered to follow-up plans and had discontinued her medication without medical advice. After she developed extrapyramidal side effects (EPSEs), haloperidol was replaced by quetiapine at 150 mg daily, titrated to 600 mg daily over 4 weeks, and the EPSEs resolved. Her pre-quetiapine white blood cell count (WBC) was 6.6, and her absolute neutrophil count was 4.0. Four weeks later, a repeat complete blood count revealed leukopenia of 1.7 and absolute neutropenia of 0.3. The following day, the leukocyte and absolute neutrophils counts were 2.0 and 0.2, respectively. MM agreed to the substitution of chlorpromazine for quetiapine. She had no clinical evidence of infection, her vital signs were normal, and she had no known prior or contemporanious medical history that might explain the laboratory findings. At quetiapine 450 mg daily, 300 mg daily, 150 mg daily, and 1 week after discontinuation, the respective WBC and absolute neutrophil counts were 2.4 and 0.4, 4.8 and 2.8, 6.2 and 4.6, 6.4 and 4.7 (within normal limits). MM refused a rechallenge with quetiapine.
This patient experienced a quetiapineassociated, dosage-related, reversible leucopenia. Hematological abnormalities have been reported with the use of atypical antipsychotic (AP) drugs, especially clozapine-induced agranulocytosis (5) . The mechanism by which these drugs induce these abnormalities remains uncertain, but they could be immunologically mediated or caused by direct bonemarrow toxicity (6) . Unlike clozapine, other atypical APs do not require adherence to a rigorous laboratory monitoring protocol. We consider it essential that physicians inform patients about the potential hematological abnormalities and educate patients about the signs and symptoms of reduced blood cell counts. Prudent clinical management also warrants routine WBC monitoring, at least during initiation of quetiapine and, possibly, other atypical APs. The possible absence of physical symptoms to alert both clinician and patient to immunological compromise jeopardizes timely identification of potentially marked neutropenia. We also think an efficient and effective strategy is needed to identify hematologically compromised patients who are at high risk of developing medical complications associated with neutropenia, before they receive atypical antipsychotics. 
Atypical Neuroleptic Malignant Syndrome With Clozapine and Subsequent Haloperidol Treatment
Clozapine can cause neuroleptic malignant syndrome (NMS), with a presentation that may be atypical in that it may occur without rigidity, fever, or changes in creatine kinase (CK) (1) . We report a patient who developed atypical NMS while taking clozapine, followed by a similar syndrome while taking haloperidol.
Mr A, aged 22 years, had a 5-year history of disorganized schizophrenia. He had previously failed trials of olanzapine, valproic acid, and risperidone. During an admission for exacerbated symptoms, a trial of clozapine was initiated. Prior to initiation, his white blood cell count (WBC) was slightly elevated, at 13.3 10 9 /L. Neutrophils, blood pressure (BP), and heart rate (HR) were normal. The clozapine was started at 25 mg daily and titrated to 325 mg daily over 16 days, while his risperidone dosage of 5 mg daily was tapered off completely. Atypically, he had mild hypertension (maximum 156/96) on clozapine, which persisted. On day 17 of clozapine treatment, he declined his medication and was observed to be more disorganized.
The following day, he vomited and was diaphoretic, agitated, and delirious, yet afebrile. He became more hypertensive and tachycardic, with marked elevations in his WBC (31.8 10 9 /L), neutrophils (24.8 10 9 /L), and CK (1442 IU/L). There was no rigidity or evidence of an infectious process. We discontinued the clozapine, and he received haloperidol 5 mg, and lorazepam 2 mg, daily. His WBC, neutrophils, BP, and HR all normalized within 24 hours. Over the following week, his delirium resolved and his CK dropped to 361 IU/L. After 5 days on haloperidol, his WBC, neutrophils, and CK suddenly rose again (17 10 9 /L, 12.8 10 9 /L, and 598 IU/L, respectively). He remained normotensive but became tachycardic. We discontinued haloperidol, and his vital signs and laboratory values subsequently normalized. Following a 1-week period of no antipsychotic (AP) treatment, Mr A was started on olanzapine without any further adverse effects.
To our knowledge, this is the first report of an atypical NMS occurring with clozapine and then repeated with another agent. It is possible that the return of this patient's NMS symptoms might have been caused by residual clozapine in his system. However, the resolution of his laboratory abnormalities and symptoms, followed by their recurrence 5 days later, makes this unlikely. Certain individuals may be sensitive to clozapine and its low affinity for dopamine receptors (2) , and this may underlie an incomplete NMS presentation. A multifactorial contribution from neurotransmitters may also explain the basis of atypical NMS (3). Haloperidol is a relatively specific dopamine blocker and the recurrence of NMS while Mr A was taking this medication lends more support to the dopaminergic theory. Nonetheless, this case highlights the possibility that patients taking clozapine may develop atypical NMS. Once NMS is present, subsequent AP medication should be introduced with caution.
